Prostate Cancer News

CancerConnect prostate cancer news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to prostate cancer. The unique daily cancer news service evaluates all aspects of prostate cancer research and reports on the developments that are most important to cancer patients and healthcare providers, while the tips and features offer insight into all aspects of prostate cancer treatment and survivorship.

Share

Prostate Cancer News


Prostate Cancer: Year in Review (February 2, 2016)

In 2015, the increased use of Oncotype DX prostate cancer test promoted changes in treatment received, resulting in greater recommendations and adoption of active surveillance. Also noteworthy is the research... Continue Reading

Survival Improved In Advanced Prostate Cancer With Early Treatment With Chemotherapy Plus Hormonal Therapy (January 29, 2016)

Excerpted from: Advances in Cancer Research And Treatment: 2015 Year In Review In a study conducted by researchers at the Dana-Farber Cancer Institute, the chemotherapy drug Taxotere® (docetaxel) administered... Continue Reading

Men Who Forgo Aggressive Treatment for Prostate Cancer Don’t Receive Appropriate Monitoring (December 9, 2015)

An increasing number of men diagnosed with low-risk prostate cancer are opting for active surveillance – closely monitoring their cancer – rather than aggressive treatment to avoid the debilitating... Continue Reading

Shorter Course of Radiation as Effective as Longer Course in Low-Risk Prostate Cancer (November 5, 2015)

A shorter course of hypofractionated radiation therapy, a treatment in which larger doses of radiation are delivered over a shorter time period than conventional radiation, appears as effective as longer... Continue Reading

Combined Hormone and Radiation Therapy Superior to Radiation Alone for Prostate Cancer Recurring After Prostatectomy (November 4, 2015)

The addition of two years of anti-androgen therapy (AAT) to radiation therapy reduces the risk of death caused by prostate cancer among men treated for a recurrence following a prostatectomy. Treatment... Continue Reading

Gene-Targeted Drug Can Treat Prostate Cancer (October 29, 2015)

According to an international consortium of researchers led by experts at The Institute of Cancer Research, London, and The Royal Marsden, a pioneering drug developed to treat women with inherited cancers... Continue Reading

Medicare Initiates Coverage for Genomic Health’s Oncotype DX® Prostate Cancer Test Effective Immediately (October 27, 2015)

Genomic Health, Inc. announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has initiated reimbursement coverage of the Oncotype DX® prostate... Continue Reading

Two-drug combination boosts survival in metastatic prostate cancer (August 17, 2015)

Newly diagnosed patients with metastatic, hormone-sensitive prostate cancer gained a dramatic survival benefit when started on two drugs simultaneously, rather than delaying the second drug until the cancer... Continue Reading

Oncotype DX Increases Use of Active Surveillance in Prostate Cancer Patients (August 5, 2015)

Genomic Health, Inc. announced that Urology Practice published results from the second clinical utility study of the Oncotype DX® prostate cancer test, showing that incorporation of the test’s Genomic... Continue Reading

More Men with Low-Risk Prostate Cancer Are Delaying Treatment until Progression (July 15, 2015)

Increasingly more men with low-risk, early-stage prostate cancer appear to choose active surveillance (or watchful waiting) instead of treatment. As a result, they’re avoiding the risk of long-term side... Continue Reading

More Prostate Cancer News

Latest Prostate Cancer News By Stage


Screening and Prevention

New Survey Reveals that Prostate Cancer Impacts Sex Lives More than Any Other Aspect of Patients’ Lives (September 11, 2014)

Washington, DC (September 8, 2014) – A recent survey conducted by ZERO – The End of Prostate Cancer and Ferring Pharmaceuticals Inc. aimed to uncover the impact of prostate cancer on patients, their caregivers, and the healthcare professionals (HCPs)... Continue Reading

September Brings Awareness to Prostate Cancer (September 4, 2014)

Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of prostate cancer programs for national prostate cancer awareness month.  Prostate cancer is the most frequently diagnosed cancer in men and is a leading cause of cancer... Continue Reading

Prostate Cancer Screening Can Take a Toll on Quality of Life (December 19, 2012)

Screening for prostate cancer carries some risks and can affect quality of life. Considering these risks is important when making the decision about whether to be screened. The results of a study that assessed both the potential benefits of screening... Continue Reading

PSA Testing May Be Appropriate for Some Men (July 25, 2012)

The American Society of Clinical Oncology (ASCO) has released a Provisional Clinical Opinion (PCO) suggesting that that men with a longer life expectancy—those with at least 10 more years to live—discuss with their physician the potential risks and... Continue Reading

Side Effects of Prostate Cancer Treatment Persist Long-Term (July 5, 2012)

Men who are treated for prostate cancer may continue to suffer from side effects 10 years after treatment, according to the results of a study published in the Journal of Clinical Oncology. Each year in the United States, more than 192,000 men are diagnosed... Continue Reading

More Screening and Prevention

Early Stage I-II (A-B)

Men Who Forgo Aggressive Treatment for Prostate Cancer Don’t Receive Appropriate Monitoring (December 9, 2015)

An increasing number of men diagnosed with low-risk prostate cancer are opting for active surveillance – closely monitoring their cancer – rather than aggressive treatment to avoid the debilitating potential side effects of surgery and radiation,... Continue Reading

Two-drug combination boosts survival in metastatic prostate cancer (August 17, 2015)

Newly diagnosed patients with metastatic, hormone-sensitive prostate cancer gained a dramatic survival benefit when started on two drugs simultaneously, rather than delaying the second drug until the cancer began to worsen, according to results of a clinical... Continue Reading

Oncotype DX Increases Use of Active Surveillance in Prostate Cancer Patients (August 5, 2015)

Genomic Health, Inc. announced that Urology Practice published results from the second clinical utility study of the Oncotype DX® prostate cancer test, showing that incorporation of the test’s Genomic Prostate Score (GPS) in treatment planning... Continue Reading

More Men with Low-Risk Prostate Cancer Are Delaying Treatment until Progression (July 15, 2015)

Increasingly more men with low-risk, early-stage prostate cancer appear to choose active surveillance (or watchful waiting) instead of treatment. As a result, they’re avoiding the risk of long-term side effects of treatment. These findings were reported... Continue Reading

Prostate Cancer in the News: Research, Treatment-Decision Making, & Promising New Therapies (January 29, 2015)

CancerConnect prostate cancer news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to prostate cancer. The unique daily cancer news service evaluates all aspects of prostate cancer research and reports... Continue Reading

More Early Stage I-II (A-B)

Locally Advanced Stage III (C)

Gene-Targeted Drug Can Treat Prostate Cancer (October 29, 2015)

According to an international consortium of researchers led by experts at The Institute of Cancer Research, London, and The Royal Marsden, a pioneering drug developed to treat women with inherited cancers can also benefit men with advanced prostate cancer. Olaparib,... Continue Reading

Two-drug combination boosts survival in metastatic prostate cancer (August 17, 2015)

Newly diagnosed patients with metastatic, hormone-sensitive prostate cancer gained a dramatic survival benefit when started on two drugs simultaneously, rather than delaying the second drug until the cancer began to worsen, according to results of a clinical... Continue Reading

Prostate Cancer in the News: Research, Treatment-Decision Making, & Promising New Therapies (January 29, 2015)

CancerConnect prostate cancer news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to prostate cancer. The unique daily cancer news service evaluates all aspects of prostate cancer research and reports... Continue Reading

Radiation Plus Androgen-Deprivation Therapy Prolongs Survival for Older Men With Prostate Cancer (January 20, 2015)

According to the results of a study recently published in the Journal of Clinical Oncology, the addition of radiation treatment to treatment with androgen-deprivation therapy (ADT) in older men with locally advanced prostate therapy prolongs survival... Continue Reading

Oncotype DX® Predicts Outcomes in Prostate Cancer Patients, Significantly Changes Treatment Recommendations (December 10, 2014)

CancerConnect News: Genomic Health, Inc. today announced results from two studies of the Oncotype DX® prostate cancer test demonstrating its value in low- and intermediate-risk prostate cancer to enable physicians and patients to avoid over- and under-treatment... Continue Reading

More Locally Advanced Stage III (C)

Metastatic Stage IV (D)

Gene-Targeted Drug Can Treat Prostate Cancer (October 29, 2015)

According to an international consortium of researchers led by experts at The Institute of Cancer Research, London, and The Royal Marsden, a pioneering drug developed to treat women with inherited cancers can also benefit men with advanced prostate cancer. Olaparib,... Continue Reading

Prostvac® Vaccine Promising in Treatment of Metastatic Castration-Resistant Prostate Cancer (June 1, 2015)

The prostate cancer vaccine Prostvac® (rilimogene galvacirepvec/rilimogene glafolivec) may be active in combination with Yervoy® (ipilimumab) in the treatment of metastatic prostate cancer that does not respond to hormone therapy. These findings were... Continue Reading

Adding Zytiga to Prednisone Improves Survival and Pain in Chemotherapy-Naive Castration-Resistant Prostate Cancer Patients (February 23, 2015)

CancerConnect News: The addition of Zytiga® (abiraterone acetate) to prednisone significantly improves survival of chemotherapy-naive patients whose prostate cancer has become resistant to hormone therapy.  Final results of the COU-AA-302 were reported... Continue Reading

Prostate Cancer in the News: Research, Treatment-Decision Making, & Promising New Therapies (January 29, 2015)

CancerConnect prostate cancer news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to prostate cancer. The unique daily cancer news service evaluates all aspects of prostate cancer research and reports... Continue Reading

Xofigo Extends Survival in Hormone-Refractory Prostate Cancer (November 6, 2014)

For patients with advanced hormone-refractory prostate cancer, the agent Xofigo® (radium-223) appears similarly effective in patients who have and have not received Taxotere® (docetaxel), a chemotherapy drug that can be used in the treatment of advanced... Continue Reading

More Metastatic Stage IV (D)

Refactory/Recurrent

Combined Hormone and Radiation Therapy Superior to Radiation Alone for Prostate Cancer Recurring After Prostatectomy (November 4, 2015)

The addition of two years of anti-androgen therapy (AAT) to radiation therapy reduces the risk of death caused by prostate cancer among men treated for a recurrence following a prostatectomy. Treatment for early prostate cancer often includes the surgical... Continue Reading

Adding Zytiga to Prednisone Improves Survival and Pain in Chemotherapy-Naive Castration-Resistant Prostate Cancer Patients (February 23, 2015)

CancerConnect News: The addition of Zytiga® (abiraterone acetate) to prednisone significantly improves survival of chemotherapy-naive patients whose prostate cancer has become resistant to hormone therapy.  Final results of the COU-AA-302 were reported... Continue Reading

Xofigo Extends Survival in Hormone-Refractory Prostate Cancer (November 6, 2014)

For patients with advanced hormone-refractory prostate cancer, the agent Xofigo® (radium-223) appears similarly effective in patients who have and have not received Taxotere® (docetaxel), a chemotherapy drug that can be used in the treatment of advanced... Continue Reading

Bayer and Orion Initiate Phase III Trial of Novel Prostate Cancer Agent ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (September 18, 2014)

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational novel oral androgen receptor (AR) inhibitor in clinical development for the treatment... Continue Reading

FDA Approves Use of Xtandi for Chemotherapy Naïve Men With Advanced Prostate Cancer (September 15, 2014)

The FDA approved the use of Xtandi® (enzalutamide) in men who have not yet received chemotherapy, significantly expanding the potential patient population eligible to be treated with the oral medicine.  Xtandi originally gained U.S. approval in 2012... Continue Reading

<More Refactory/Recurrent

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS